Pulmatrix Receives $30,200,000 Series B Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    99 Hayden Avenue Lexington, MA 02421
  • Company Description
    Pulmatrix Inc. is a pharmaceutical company developing inhalable aerosols and enabling technologies that help control respiratory infectious disease and human-source airborne contamination.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Pulmatrix plans to use the new money to finance “multiple clinical trials” in 2010 and 2011 against a number of respiratory diseases, according to a company statement.
  • M&A Terms
  • Venture Investor
    ARCH Venture Partners
  • Venture Investor
    Novartis BioVenture Fund
  • Venture Investor
    Polaris Venture Partners
  • Venture Investor
    5AM Ventures

Trending on Xconomy